[go: up one dir, main page]

WO1996017635A1 - Activation de methodes de traitement moleculaires par stimulation electromagnetique controlee - Google Patents

Activation de methodes de traitement moleculaires par stimulation electromagnetique controlee Download PDF

Info

Publication number
WO1996017635A1
WO1996017635A1 PCT/IB1995/001113 IB9501113W WO9617635A1 WO 1996017635 A1 WO1996017635 A1 WO 1996017635A1 IB 9501113 W IB9501113 W IB 9501113W WO 9617635 A1 WO9617635 A1 WO 9617635A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
coils
container
electromagnetic field
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1995/001113
Other languages
English (en)
Inventor
Michael Richard Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifetech Corp
Original Assignee
Lifetech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifetech Corp filed Critical Lifetech Corp
Priority to AU39350/95A priority Critical patent/AU3935095A/en
Publication of WO1996017635A1 publication Critical patent/WO1996017635A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0094—Gaseous substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/20—Gaseous substances, e.g. vapours
    • A61L2/202—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment

Definitions

  • the present invention relates broadly to the enhancement of treatment processes carried out on human or animal body fluids such as whole blood, serum, plasma, and packed red blood cells; and as well, bone marrow and seminal fluids, including blood by-products, blood components and related by-products or substances. Also included are fluids that may be administered to mammals, including humans, such as saline or glucose intravenous solutions and the like; and fluid nutrient media such as are employed to grow bacteria, viruses, cells, parasites, and the like. For convenience, all of the aforementioned fluids will hereafter be referred to collectively as "biological fluids".
  • the present invention has been evolved primarily, but not exclusively, in connection with the ozone treatment of blood and blood products.
  • Gas sterilization of blood using ozone has been widely reported and is discussed, for example, in an article entitled “Are Worry-Free Transfusions Just a Whiff of Ozone Away?" by Albert C.
  • the concentration of ozone in the treating atmosphere is said to be in the range of about 1 to 100 ppm, and usually in the range of from about 1 to 20 ppm.
  • the ozone level was at approximately 2 ppm, and apparently was even lower since the ozone was mixed with filtered air before being contacted with the blood in the rotating bottle.
  • the patentee emphasizes the need for what are referred to as "mild" contact conditions, apparently referring to the very low concentrations of ozone which are used.
  • sprayable biological fluid By the term “sprayable biological fluid” is meant that the biological fluid behaves mechanically like a liquid, and can be dispersed into a gas phase as discrete droplets.
  • a fluid e.g. in the case of blood, need not be entirely liquid or homogeneous, but can e.g. consist of minute bodies such as cells contained in a liquid carrier.
  • a chamber for receiving and collecting the liquid (such as blood) which is to be contacted with the oxygenating gas, such as ozone.
  • Blood or other biological fluid to be oxygenated is provided to a reservoir.
  • a gas/biological fluid delivery tube comprising an outer biological fluid delivery tube and a coaxially spaced inner gas delivery tube, extends into the reservoir, where the outer tube terminates at an open end.
  • the inner tube extends through the reservoir to a point outside the chamber, so that it may receive oxygenating gas at its input end.
  • the distal end of the delivery tube comprises a spray nozzle.
  • the venturi effect generated by flow of the oxygenating gas from the gas delivery tube discharge to a spaced nozzle orifice causes blood in the reservoir to be aspirated into and contacted with the gas stream, and to issue from the nozzle orifice as a dispersed spray of liquid droplets.
  • a spray collection surface is located within the chamber in the spray path of the liquid droplets, which collects substantially the entirety of the droplets of oxygenated liquid, which are then provided to a discharge conduit. This collection surface is spaced from the spray orifice a distance selected so that the droplets impinge on the collection surface at relatively low velocity and form a film on the surface, where further contact with the gas can also be effected.
  • the method of contact achieved in the said apparatus is very effective in that high energy mechanical impact of the droplets with the collection surface is avoided, whereby hemolysis effects are eliminated or greatly reduced. Much higher concentrations of ozone can be safely utilized in this apparatus than have heretofore been taught.
  • the pulsed electromagnetic field will increase the susceptibility of the cells or other structures within the fluid to the effect of the other treatment process. This may occur as a result of one or more mechanisms that take place at the cellular level including enhancement of ion exchange, proton precession and, where red blood cells are present, domain rotation of ferrous compounds in those cells.
  • the treatment mechanism used in conjunction with the electromagnetic field may include one or more of a number of treatment mechanisms that are known in themselves, including ozone/oxygen treatment, treatment with drugs such as anti -viral or anti-cancer compounds, cultures or other known treatment mechanisms.
  • the blood or other biological fluid is withdrawn from the body and treated externally, although ii is possible that the treatment may be applied directly to the patient.
  • an electromagnetic field could be applied to the whole or part of a patient's body while the drug or other therapy is in progress.
  • Treatment external to the body is believed to be preferable on the basis that there would then be no interference or "screening" of the treatment by other mechanisms that might be going on within the body, or screening or other disturbances caused by body organs.
  • a small volume of the fluid (e.g. 10-500 mL) will be withdrawn from the patient (or from a supply in a blood bank or the like ) and placed in a special container that is designed to infuse ozone/oxygen gas mixtures or drugs appropriate to the treatment required.
  • the special container is surrounded with a coil which is designed to apply a pulsed electromagnetic field to the fluid within the container.
  • the biological fluid can also be treated on a continuous basis, e.g. by passing a continuous stream of the fluid through a spray apparatus of the type disclosed in the aforementioned 5,366,696 patent, while simultaneously imposing .an electromagnetic field in the region of the intermixed spray droplets and ozone.
  • Figure 1 is a schematic illustration of a blood treatment container surroimded by a coil, for treating blood in accordance with the invention
  • Figure 2 is a schematic illustration in more detail of the container shown in Figure 1 ;
  • Figure 3 is a side view illustrating an alternative form of container
  • Figure 4 is a detail perspective view of part of the container of Figure 2;
  • Figure 5 is a simplified schematic cross-sectional view illustrating use of the invention in conjunction with a spray device in which a biological fluid is being oxygenated;
  • Figure 6 is a schematic illustration of an arrangement of electromagnetic coils for use in a "whole body" treatment apparatus according to the invention.
  • Figures 7 and 8 illustrate an alternative configuration of coils that may be used for whole body treatment or for treating a specific limb or other part of the body
  • Figure 9 illustrates an arrangement for energizing the coils in pairs, in an arrangement such as that shown in Figure 7 with additive flux lines or fields;
  • Figure 10 shows in detail the flux lines that are achieved in the arrangement of Figure 9;
  • Figure 11 is a more detailed illustration of part of Figure 9 showing opposing flux lines or fields;
  • Figure 12 shows an alternative arrangement for energizing the coils of Figure 9 with additive flux lines or fields
  • Fig. 13 shows the flux lines in a cross-section of one of the actual coils of Fig. 12 with additive flux lines or fields;
  • Figures 14 and 15 illustrate cross sectional and perspective views of a specific coil design
  • Figure 16 is a diagrammatic illustration of a shielding method that may be used for the coils
  • FIGS 17 and 18 illustrate possible coil switching arrangements
  • Figures 19 and 20 illustrate electromagnetic field patterns.
  • a blood treatment container is generally indicated by reference numeral 20 and is of generally cylindrical form with three inlet/outlet ports 22 extending upwardly from its top surface.
  • the container itself is molded in a suitable plastic material.
  • the container is shown disposed within a coil 24 that is wound in a helical configuration so as to define a central space of slightly larger diameter than the container.
  • the ends of the coil are connected to a conventional pulse train generator represented by the square wave form indicated at 26 in Figure 1.
  • the generator is capable of applying a continuous train of pulses to the coil imposing a pulsed electromagnetic field on the blood or other liquid within container 20.
  • the pulsed wave form is illustrated as a square wave, other pulsed shapes known in the art can be used, such as a half-sine, saw tooth, or a triangular wave shape.
  • FIG. 2 shows container 20 in more detail and separately from coil 24.
  • the ports 22 at the top of the container comprise a blood inlet port 22a at one side of the container, a central port 22b through which an ozone/oxygen gas mixture can be delivered to the container, and a gas exhaust port 22c diametrically opposite inlet port 22a.
  • the inlet and outlet ports 22a and 22c respectively simply communicate with the interior volume of the container.
  • Port 22b on the other hand is defined by the upper end portion of a tube 28 which is disposed generally on the vertical centerline of the container, and from which radiate outwardly a series of thin perforated tubes 30 through which the oxygen/gas mixture is bubbled into the blood within container 22.
  • the tubes are disposed in groups that are vertically spaced along tube 28.
  • a separator plate 32 in the form of a fine mesh extends across the container above each group of tubes, to form a barrier preventing bubbles rising within the container.
  • a separator plate 32 in the form of a fine mesh extends across the container above each group of tubes, to form a barrier preventing bubbles rising within the container.
  • there are three groups of tubes with one pair of tubes in each group although it is to be understood that both the number of groups and the number of tubes in each group can vary.
  • Figure 3 illustrates a generally similar form of container, denoted 20' but which has only an inlet port 22a' and an outlet 22c'.
  • the ozone/oxygen gas mixture is introduced through a tube 34 having respective limbs 36 and 38 that extend laterally from the tube at different levels within the container, and above each of which is disposed a separator plate 32 of the same form as the separator plates shown in Fig. 2.
  • Figure 4 essentially shows a modification of Fig. 2. and also serves to illustrate in some detail the effect of the separator plate 32 within any of the containers illustrated.
  • the container has a central vertical tube 28' similar to tube 28 of Fig. 2.
  • the tube itself is perforated (as indicated for example at 40), so that ozone/oxygen bubbles escape into the blood directly from the tube.
  • the bubbles collect below the mesh (typically 50-400 mesh size) for ready absorption by the blood or other liquid in the container.
  • bubbling will be of short duration, sufficient to build up a layer of bubbles at the underside of each separator plate and provide for a predetermined ozone concentration given the amount of blood within the container. Bubbling will take place immediately before or during application of a pulsed electromagnetic field to the blood by means of the coil 24 ( Figure 1 ).
  • the blood or other body fluid is treated externally of the body in volumes or "units" typically in the range 10-500 mL. i.e. the blood is treated on a batch basis.
  • the blood unit is discharged from the container and. for example, returned to the patient or to a blood storage facility.
  • it may be necessary to treat only a relatively small volume of blood per patient, in order to provide an effective treatment.
  • FIG. 5 a schematic cross-section appears illustrating use of the invention in conjunction with a spray device 60 in which a biological fluid such as blood is being oxygenated.
  • a biological fluid such as blood is being oxygenated.
  • the general mode of operation of the device is similar to that of the aforementioned U.S. patent No. 5.366.696; and thus it may be assumed that blood or other biological fluid of interest is to be oxygenated by treatment with ozone, the blood being intermixed with the ozone as a highly dispersed spray of droplets.
  • the ozone flow is provided to the nozzle 62 via conduit 64, whereby the venturi effect generated in the region 66 aspirates blood from a reservoir (not shown) via the conduit 68, with the ozone and blood being mixed at region 66 and then discharged as a spray of fine droplets from nozzle orifice 70.
  • the nozzle is contained within the chamber 72, into which the spray is discharged.
  • the oxygenated droplets are collected at the inner walls of chamber 72, and then the oxygenated blood or other biological fluid is taken as product via outlet 74. Excess and spent gases are discharged at outlet 75.
  • the chamber is formed of a dielectric insulator such as a suitable plastic, and is enveloped by a coil 76, the function of which is analogous to coil 24 of Figure 1.
  • Input terminals 78 enable a pulsed e.m.f. to be applied to coil 76. which as in prior embodiments, generates a pulsed electromagnetic field within chamber 72. and thus throughout the region of the spray. It will be evident that a film of blood deposited on the chamber interior walls, or a film that may be formed in any other manner in the interior of the chamber (e.g. a falling film), can be subjected to the electromagnetic field in like manner.
  • the electromagnetic field of the invention will generally be pulsed at a frequency of no higher than 85 Hz. with 5 to 85 Hz being preferable, and 10 to 15 Hz being more preferable.
  • Field intensities should preferably be in the 1 to 25 gauss range, but considerably higher fields can be used, depending upon the physical and biological properties of the fluids being treated, and the duration of exposure to the field. With most biological fluids the upper limit will effectively be that at which substantial cellular damage occurs, and in some instances this can be in the hundreds or even thous-ands of gauss range.
  • Fig. 6 shows an apparatus designed to permit such "whole body" treatment.
  • the particular apparatus shown has been designed for treating spinal injuries but may be used to apply an electromagnetic field to the whole of a patient's body, for other types of treatment.
  • a bed of suitable non-metallic material is indicated at 42 and an array 44 of helical coils is disposed below the bed and has connections 46 to a suitable pulse train generator (not shown).
  • the individual coils of the array 44 are denoted 48 and it will be seen that the coils are disposed with their axes generally normal to the patient (who will be supported on the bed) and connected in parallel for providing a localized electromagnetic field effect. Connecting the coils in parallel reduces resistance and inductance, which is important for pulse fidelity.
  • the pulse retains its high/low frequency components while making it more effective for therapeutic use.
  • Figs. 7 and 8 show a cylindrical form of electromagnetic treatment apparatus 50 defining an open central space or cavity 52 within a surrounding sleeve 53.
  • the apparatus can be sized as appropriate in terms of length and diameter to receive the whole of a patient's body or a particular part such as an arm, leg or the neck, depending on the area to be treated.
  • the coil configuration is as shown in Fig. 7, namely an array of coils 55 extending radially with respect to the longitudinal axis of the cylindrical apparatus.
  • the coils in each array are connected in parallel to produce a concentrated localized field effect.
  • a series of such coil arrays may be provided in parallel planes based along the length of the cylinder, according to the required overall length of the apparatus, and the desired treatment locations.
  • Fig. 7. it should be noted that the coil configuration shown is suitable for providing an electromagnetic field around a container containing blood or other liquid to be treated, for example, a container of the form shown in any of Figs. 1 to 4.
  • Fig. 9 illustrates the fact that the coils in an array such as that shown in Fig. 7 can be energized by the drive input 53 as independent series of coil pairs in which the pairs of coils are diametrically opposed to one another.
  • Four coils 57a. 57b. 57c and 57d at one side of the Figure are thus connected via conductor ring 59 to one side of the 11 drive input 53; while coils 61a, 61 b. 61c and 61d are connected via conductor ring 63 to the other side of drive input 53.
  • Fig. 9 shows the major flux lines between the coils in each pair, while Fig. 10 shows the full pattern of flux lines.
  • Fig. 1 1 shows the flux line configuration in which the coils are energized alternately in pairs.
  • Figs. 12 and 13 show a still further arrangement in which the coils are connected in a cross-field configuration; the flux lines are shown in Fig. 12.
  • the coil configuration will be chosen according to the nature of the treatment required. For example, in some situations, it may be desired to provide a very localized, concentrated magnetic effect, whereas in other situations, a more diffuse or general effect may be desired.
  • Fig. 14 .and 15 illustrates a particular coil configuration in which multiple concentric coils are used and in which the ability is provided to switch individual coils in and out of the circuit to change the field strength of the apparatus as a whole.
  • four helical coils are shown, although the number of coils may vary.
  • the coils are wound in close proximity to each other and spaced apart as individual coils having the same time/phase relationship so that the summation of all coil sets yields maximum field strength when energized.
  • This coil design feature ensures that the inductance, capacitance and resistance of the coils are kept low so as to produce a faithful reproduction of the energizing pulse wave form. In other words, the driving pulse wave form retains all of its high and low frequency characteristics.
  • each of the coils is driven separately by an individual power amplifier but the coils are synchronized.
  • each coil may be of 250 turns and be driven at 2.5 amps RMS pulse power.
  • the total electromagnetic field strength at the center of the coils may be about 412 Gauss. It should again be noted that an advantage of this particular coil design is the ability to switch individual coils in and out of the circuit to change the field strength.
  • the individual coils are shielded to minimize the effects of radiated electric field while retaining a faithful reproduction of the electromagnetic pulse.
  • Fig. 16 shows a thin copper foil shield 54 which surrounds one of the coils except for an open end 54a, and which is grounded at 56.
  • the electromagnetically pulsed coils are designed and connected in the circuit such that individual coils or coil pairs can be switched in or out of the circuit and driven by separate pulse driving amplifiers. This facilitates flexibility in changing electromagnetic field strength and field position.
  • Fig. 14 shows four separate coils that can be switched in or out of the circuit separately or switched in the circuit altogether, for example by a switching arrangement such as that shown in Fig. 18.
  • Fig. 12 shows a circuit of separately connected coil pairs which can be alternatively switched in pairs or switched in circuit altogether, for example by a switching arrangement such as that shown in Fig. 17.
  • Figs. 19 and 20 simply illustrate conventional electromagnetic field patterns for "additive” and “opposing” coils respectively.
  • hemoglobin is of particular significance, and is the substance within red blood cells that carries oxygen.
  • Each red blood cell has some 270 million hemoglobin molecules and is an agglomeration of four wound-up chains, each of which encloses an iron atom capable of retaining one oxygen molecule.
  • one hemoglobin molecule can carry four molecules of oxygen -- one blood cell more than one billion molecules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • External Artificial Organs (AREA)

Abstract

On obtient un effet synergique en traitant des liquides biologiques tels que le sang, le sperme ou la moelle osseuse, par une méthode classique tout en les exposant à un champ électromagnétique pulsé. La méthode de traitement selon l'invention peut consister à administrer un mélange d'ozone ou d'oxygène/ozone gazeux pour inactiver les virus présents dans le sang ou un autre liquide, ou à administrer un médicament. Il est préférable de traiter le liquide à l'extérieur du corps, par exemple dans une unité d'un certain volume. Le traitement in vivo est également décrit.
PCT/IB1995/001113 1994-12-09 1995-12-11 Activation de methodes de traitement moleculaires par stimulation electromagnetique controlee Ceased WO1996017635A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39350/95A AU3935095A (en) 1994-12-09 1995-12-11 Activation of molecular processes by controlled electromagnetic stimulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424913.3 1994-12-09
GBGB9424913.3A GB9424913D0 (en) 1994-12-09 1994-12-09 Enhancement of treatment processes

Publications (1)

Publication Number Publication Date
WO1996017635A1 true WO1996017635A1 (fr) 1996-06-13

Family

ID=10765700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/001113 Ceased WO1996017635A1 (fr) 1994-12-09 1995-12-11 Activation de methodes de traitement moleculaires par stimulation electromagnetique controlee

Country Status (3)

Country Link
AU (1) AU3935095A (fr)
GB (1) GB9424913D0 (fr)
WO (1) WO1996017635A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761268A1 (fr) * 1997-03-26 1998-10-02 Jean Claude Mainguy Dispositif de traitement des cellules tumorales a l'aide de signaux electromagnetiques
GB2323791A (en) * 1997-04-01 1998-10-07 Johann Zimmermann Electromagnetic pen for skin treatment
WO2000004951A1 (fr) * 1998-07-22 2000-02-03 Mainguy Jean Claude Dispositif de traitement des cellules tumorales
WO2005025712A3 (fr) * 2003-07-31 2006-02-09 Lipidviro Tech Inactivation virale a l'aide d'ozone
US7736494B2 (en) 2003-07-31 2010-06-15 Acquisci, Inc. Ozone delivery system including a variable pitch gas-fluid contact device
WO2016043649A1 (fr) * 2014-09-15 2016-03-24 Johan Sjöholm Appareil et procédé pour mettre en contact le sang avec de l'ozone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4865747A (en) * 1988-01-27 1989-09-12 Aqua-D Corp. Electromagnetic fluid treating device and method
US4879045A (en) * 1986-01-13 1989-11-07 Eggerichs Terry L Method and apparatus for electromagnetically treating a fluid
WO1990015594A1 (fr) * 1989-06-16 1990-12-27 Liburdy, Robert, P. Administration de substances chimiques et de medicaments par des liposomes declenchee par champ electromagnetique
US5084003A (en) * 1989-11-24 1992-01-28 Dragan Susic Magnetic massage therapy device
US5386837A (en) * 1993-02-01 1995-02-07 Mmtc, Inc. Method for enhancing delivery of chemotherapy employing high-frequency force fields

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879045A (en) * 1986-01-13 1989-11-07 Eggerichs Terry L Method and apparatus for electromagnetically treating a fluid
US4865747A (en) * 1988-01-27 1989-09-12 Aqua-D Corp. Electromagnetic fluid treating device and method
WO1990015594A1 (fr) * 1989-06-16 1990-12-27 Liburdy, Robert, P. Administration de substances chimiques et de medicaments par des liposomes declenchee par champ electromagnetique
US5084003A (en) * 1989-11-24 1992-01-28 Dragan Susic Magnetic massage therapy device
US5386837A (en) * 1993-02-01 1995-02-07 Mmtc, Inc. Method for enhancing delivery of chemotherapy employing high-frequency force fields

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761268A1 (fr) * 1997-03-26 1998-10-02 Jean Claude Mainguy Dispositif de traitement des cellules tumorales a l'aide de signaux electromagnetiques
GB2323791A (en) * 1997-04-01 1998-10-07 Johann Zimmermann Electromagnetic pen for skin treatment
GB2323791B (en) * 1997-04-01 1999-09-01 Johann Zimmermann Electromagnetic pen
WO2000004951A1 (fr) * 1998-07-22 2000-02-03 Mainguy Jean Claude Dispositif de traitement des cellules tumorales
WO2005025712A3 (fr) * 2003-07-31 2006-02-09 Lipidviro Tech Inactivation virale a l'aide d'ozone
US7736494B2 (en) 2003-07-31 2010-06-15 Acquisci, Inc. Ozone delivery system including a variable pitch gas-fluid contact device
WO2016043649A1 (fr) * 2014-09-15 2016-03-24 Johan Sjöholm Appareil et procédé pour mettre en contact le sang avec de l'ozone
CN107073149A (zh) * 2014-09-15 2017-08-18 桑格公司 将血液与臭氧接触的装置和方法
EP3193948A4 (fr) * 2014-09-15 2018-06-20 Sangair AB Appareil et procédé pour mettre en contact le sang avec de l'ozone
JP2021176566A (ja) * 2014-09-15 2021-11-11 サンゲア アクチエボラグSangair AB 血液をオゾンと接触させるための装置及び方法
US11426505B2 (en) 2014-09-15 2022-08-30 Sangair Ab Apparatus and method for contacting blood with ozone

Also Published As

Publication number Publication date
GB9424913D0 (en) 1995-02-08
AU3935095A (en) 1996-06-26

Similar Documents

Publication Publication Date Title
EP0788392B1 (fr) Therapie genique et chimique par electroporation au moyen de champs electriques induits
US7011790B2 (en) Non-thermal disinfection of biological fluids using non-thermal plasma
AU642020B2 (en) Internal tissue medication permeating apparatus and method
CA2266347C (fr) Catheter d'electroporation et d'iontophorese comportant un ballonnet poreux
WO1998056302A1 (fr) Dispositif magnetique interne pour ameliorer la therapie medicamenteuse
DE68922456D1 (de) Krebsbehandlung.
CN101821378A (zh) 生物反应器
US11364390B2 (en) Apparatus for treating pathological cells
WO1996017635A1 (fr) Activation de methodes de traitement moleculaires par stimulation electromagnetique controlee
US20220362451A1 (en) Apparatus And Method For Contacting Blood With Ozone
US20030118473A1 (en) Method and apparatus for ozone decontamination of biological liquids
RU2001110081A (ru) Способ обеспечения косметической/медицинской терапии
AU2021224972A1 (en) Medical device and method for producing a plasma-activated liquid
RU2070059C1 (ru) Способ очистки крови от вируса спид
CN1065798A (zh) 血液离子治疗仪
WO2023244864A1 (fr) Appareil de traitement thérapeutique à l'ozone et procédé d'utilisation pour traiter un emplacement de traitement
JP3315782B2 (ja) 光化学反応による血液中抗癌剤変換装置
MXPA01010024A (en) Method of providing cosmetic/medical therapy
Adachi Steven KAALI & Paul SCHWOLSKY Blood Electrification vs AIDS (&c)
JPS6479122A (en) Treatment of malignant tumor and device therefor
WO2001089601A1 (fr) Procede et dispositif de decontamination par l'ozone de liquides biologiques
RU94022192A (ru) Основа лекарственного средства

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 849958

Date of ref document: 19970812

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA